BMT-13
A Phase II Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Myeloablative Fludarabine/Busulfan and Post-Transplant Cyclophosphamide (PTCY) for Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients with High-Risk AML, CML, and MDS
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 38 patients (estimated)
- Sponsors
- University of Illinois at Chicago
- Tags
- Pre-Allogeneic Stem Cell Transplant, Radiation Therapy
- Trial Type
- Treatment
- Last Update
- SparkCures ID
- 2057
- NCT Identifier
- NCT06802315
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.